NCT00297180已完成2 期
A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 136
- 试验地点
- 4
- 主要终点
- Percentage change in body weight from baseline to Week 12.
研究概览
简要总结
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Percentage change in body weight from baseline to Week 12.
时间窗: from baseline to Week 12.
次要结局
- Blood levels of GW869682 at the Week 2 and Week 11.(at the Week 2 and Week 11)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR enterography in patients not taking metformitype 2 diabetes mellitusJPRN-UMIN000045137Kobe university5
尚未招募
不适用
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR enterography in patients taking imeglimitype 2 diabetes mellitusJPRN-UMIN000045345Kobe university5
尚未招募
Unknown
Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR Enterography in patients taking imeglimitype 2 diabetes mellitusJPRN-UMIN000049426Kobe University10
已完成
2 期
Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.Renal ImpairmentNCT03131479Novartis Pharmaceuticals53
已完成
2 期
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT00422487CymaBay Therapeutics, Inc.60